fluorouracil has been researched along with Headache in 10 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
Excerpt | Relevance | Reference |
---|---|---|
" A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 9.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
" She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progression, but developed unconsciousness, irritability, and headache shortly after initiation of treatment." | 8.31 | Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy. ( Xie, L, 2023) |
"For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer." | 7.96 | Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020) |
"Headaches have been reported as a potential side effect of capecitabine therapy." | 7.74 | Capecitabine-induced headache responding to diltiazem. ( Fakih, MG; Raman, AK, 2007) |
" Patients exhibited high compliance in dosing administration." | 6.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
" A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 5.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
" She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progression, but developed unconsciousness, irritability, and headache shortly after initiation of treatment." | 4.31 | Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy. ( Xie, L, 2023) |
"For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer." | 3.96 | Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020) |
"Headaches have been reported as a potential side effect of capecitabine therapy." | 3.74 | Capecitabine-induced headache responding to diltiazem. ( Fakih, MG; Raman, AK, 2007) |
"7% of patients experienced grade 3 and 4 adverse events, respectively." | 2.80 | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. ( Campone, M; Citron, ML; Dang, CT; Dirix, L; Gianni, L; Krop, IE; Romieu, G; Smitt, M; Suter, TM; Xu, N; Zamagni, C, 2015) |
" Patients exhibited high compliance in dosing administration." | 2.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (40.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
Xie, L | 1 |
Raina, AJ | 1 |
Gilbar, PJ | 1 |
Grewal, GD | 1 |
Holcombe, DJ | 1 |
Nguyen, MT | 1 |
Stoianovici, R | 1 |
Brunetti, L | 1 |
Krop, IE | 1 |
Suter, TM | 1 |
Dang, CT | 1 |
Dirix, L | 1 |
Romieu, G | 1 |
Zamagni, C | 1 |
Citron, ML | 1 |
Campone, M | 1 |
Xu, N | 1 |
Smitt, M | 1 |
Gianni, L | 1 |
Peterson, DE | 1 |
Barker, NP | 1 |
Akhmadullina, LI | 1 |
Rodionova, I | 1 |
Sherman, NZ | 1 |
Davidenko, IS | 1 |
Rakovskaya, GN | 1 |
Gotovkin, EA | 1 |
Shinkarev, SA | 1 |
Kopp, MV | 1 |
Kulikov, EP | 1 |
Moiseyenko, VM | 1 |
Gertner, JM | 1 |
Firsov, I | 1 |
Tuleneva, T | 1 |
Yarosh, A | 1 |
Woon, CW | 1 |
Raman, AK | 1 |
Fakih, MG | 1 |
Köhne, CH | 1 |
Hiddemann, W | 1 |
Schüller, J | 1 |
Weiss, J | 1 |
Lohrmann, HP | 1 |
Schmitz-Hübner, U | 1 |
Bodenstein, H | 1 |
Schöber, C | 1 |
Wilke, H | 1 |
Grem, J | 1 |
Tan, EH | 1 |
Ang, PT | 1 |
Khoo, KS | 1 |
Stuart, K | 1 |
Tessitore, J | 1 |
Huberman, M | 1 |
Noguerón, E | 1 |
Berrocal, A | 1 |
Albert, A | 1 |
Camps, C | 1 |
Vicent, JM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Ca[NCT01196052] | Phase 2 | 153 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT01196052)
Timeframe: From the start to the end of radiotherapy treatment (up to 51 weeks)
Intervention | Percentage of participants (Number) |
---|---|
Trastuzumab Emtansine | 94.7 |
Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
Intervention | Percentage of participants (Number) |
---|---|
Trastuzumab Emtansine | 82.4 |
(NCT01196052)
Timeframe: From the start to the end of concurrent hormonal therapy (up to 51 weeks)
Intervention | Percentage of participants (Number) |
---|---|
Trastuzumab Emtansine | 69.4 |
(NCT01196052)
Timeframe: From the start to the end of concurrent radiotherapy (up to 51 weeks)
Intervention | Percentage of participants (Number) |
---|---|
Trastuzumab Emtansine | 94.9 |
A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association [NYHA] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of < 50%. (NCT01196052)
Timeframe: Baseline to 12 weeks after the start of trastuzumab emtansine treatment
Intervention | Percentage of participants (Number) |
---|---|
Trastuzumab Emtansine | 0 |
Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery. (NCT01196052)
Timeframe: Day of surgery
Intervention | Percentage of participants (Number) |
---|---|
Trastuzumab Emtansine | 56.0 |
The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF < 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
Intervention | Percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
At least 1 adverse event (AE) | At least 1 serious adverse event | An AE leading to treatment discontinuation | An AE leading to dose delay | An AE leading to dose reduction | Symptomatic cardiac dysfunction | An asymptomatic decline in LVEF | Deaths | |
Trastuzumab Emtansine | 98.6 | 10.1 | 13.5 | 29.1 | 21.6 | 0.0 | 2.7 | 0 |
4 trials available for fluorouracil and Headache
Article | Year |
---|---|
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2015 |
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea | 2009 |
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1995 |
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem | 1994 |
6 other studies available for fluorouracil and Headache
Article | Year |
---|---|
Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy.
Topics: Calcium; Cisplatin; Docetaxel; Edema; Female; Fluorouracil; Headache; Humans; Leucovorin; Middle Age | 2023 |
Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature.
Topics: Administration, Intravenous; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Glucocortico | 2020 |
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Brain Dise | 2017 |
Capecitabine-induced headache responding to diltiazem.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diltiazem; Female; Fluorouracil | 2007 |
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P | 1996 |
[Acute cerebellar syndrome due to 5-fluorouracil].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cerebellar Ataxia; Fluorouracil; Headache; Humans; M | 1997 |